Gene Therapy in Mice Holds Promise for ALS and Dementia

Neuroresearchers at Macquarie University in Australia say they have developed a single-dose genetic medicine that has halted the progression of both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) in mice. The team, which believes its approach...

Amylyx’s ALS drug Albrioza rebuffed by EU regulator—again

Even as Amylyx’s ALS drug gains steam in the U.S. after a long-awaited FDA approval, the company is struggling with regulatory hurdles overseas. This week, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against...

AcuraStem and Takeda Collaborate on Innovative ALS Treatment

AcuraStem, a pioneering patient-based biotechnology company specializing in neurodegenerative disease treatments, has announced a groundbreaking partnership with Takeda to develop and commercialize targeted therapeutics for Amyotrophic Lateral Sclerosis (ALS) and...